Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.44
DEPO's Cash to Debt is ranked higher than
75% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. DEPO: 2.44 )
DEPO' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 2.44

Equity to Asset 0.36
DEPO's Equity to Asset is ranked higher than
52% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. DEPO: 0.36 )
DEPO' s 10-Year Equity to Asset Range
Min: -2.63   Max: 0.97
Current: 0.36

-2.63
0.97
Interest Coverage 1.73
DEPO's Interest Coverage is ranked lower than
51% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.95 vs. DEPO: 1.73 )
DEPO' s 10-Year Interest Coverage Range
Min: 1.73   Max: 9999.99
Current: 1.73

1.73
9999.99
F-Score: 5
Z-Score: 2.61
M-Score: -1.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 36.58
DEPO's Operating margin (%) is ranked higher than
97% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.59 vs. DEPO: 36.58 )
DEPO' s 10-Year Operating margin (%) Range
Min: -12972.91   Max: 72.49
Current: 36.58

-12972.91
72.49
Net-margin (%) 33.40
DEPO's Net-margin (%) is ranked higher than
97% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.31 vs. DEPO: 33.40 )
DEPO' s 10-Year Net-margin (%) Range
Min: -14964.35   Max: 75.05
Current: 33.4

-14964.35
75.05
ROE (%) 47.40
DEPO's ROE (%) is ranked higher than
99% of the 874 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. DEPO: 47.40 )
DEPO' s 10-Year ROE (%) Range
Min: -1132.2   Max: 539.92
Current: 47.4

-1132.2
539.92
ROA (%) 16.90
DEPO's ROA (%) is ranked higher than
95% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. DEPO: 16.90 )
DEPO' s 10-Year ROA (%) Range
Min: -201.37   Max: 73.87
Current: 16.9

-201.37
73.87
ROC (Joel Greenblatt) (%) 1082.16
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.17 vs. DEPO: 1082.16 )
DEPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2396.53   Max: 7997.51
Current: 1082.16

-2396.53
7997.51
Revenue Growth (%) 15.60
DEPO's Revenue Growth (%) is ranked higher than
83% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. DEPO: 15.60 )
DEPO' s 10-Year Revenue Growth (%) Range
Min: -69.7   Max: 420.5
Current: 15.6

-69.7
420.5
EBITDA Growth (%) 46.00
DEPO's EBITDA Growth (%) is ranked higher than
94% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. DEPO: 46.00 )
DEPO' s 10-Year EBITDA Growth (%) Range
Min: -55.8   Max: 84.2
Current: 46

-55.8
84.2
EPS Growth (%) 120.50
DEPO's EPS Growth (%) is ranked higher than
99% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. DEPO: 120.50 )
DEPO' s 10-Year EPS Growth (%) Range
Min: -59.5   Max: 180.9
Current: 120.5

-59.5
180.9
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DEPO Guru Trades in Q4 2013

Steven Cohen 1,867,300 sh (New)
Jim Simons 129,338 sh (New)
Paul Tudor Jones 19,853 sh (New)
» More
Q1 2014

DEPO Guru Trades in Q1 2014

Paul Tudor Jones 63,632 sh (+220.52%)
Jim Simons Sold Out
Steven Cohen 17,403 sh (-99.07%)
» More
Q2 2014

DEPO Guru Trades in Q2 2014

George Soros 75,600 sh (New)
Joel Greenblatt 937,085 sh (New)
Paul Tudor Jones 40,112 sh (-36.96%)
» More
Q3 2014

DEPO Guru Trades in Q3 2014

Steven Cohen 448,900 sh (New)
Joel Greenblatt 1,637,713 sh (+74.77%)
Paul Tudor Jones 64,690 sh (+61.27%)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 74.77%0.11%$10.69 - $15.49 $ 15.7418%1637713
George Soros 2014-09-30 Sold Out 0.01%$10.69 - $15.49 $ 15.7418%0
Joel Greenblatt 2014-06-30 New Buy0.16%$10.57 - $14.37 $ 15.7423%937085
George Soros 2014-06-30 New Buy0.01%$10.57 - $14.37 $ 15.7423%75600
Joel Greenblatt 2012-06-30 Sold Out 0.01%$4.97 - $6.6 $ 15.74177%0
Daniel Loeb 2011-09-30 Sold Out 0.6154%$5 - $8.74 $ 15.74137%0
Joel Greenblatt 2011-09-30 Add 48.97%$5 - $8.74 $ 15.74137%15244
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 11.80
DEPO's P/E(ttm) is ranked higher than
97% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.00 vs. DEPO: 11.80 )
DEPO' s 10-Year P/E(ttm) Range
Min: 2.36   Max: 121.85
Current: 11.8

2.36
121.85
P/B 3.51
DEPO's P/B is ranked higher than
71% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. DEPO: 3.51 )
DEPO' s 10-Year P/B Range
Min: 2   Max: 48.18
Current: 3.51

2
48.18
P/S 4.06
DEPO's P/S is ranked higher than
72% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. DEPO: 4.06 )
DEPO' s 10-Year P/S Range
Min: 1.38   Max: 752
Current: 4.06

1.38
752
EV-to-EBIT 6.91
DEPO's EV-to-EBIT is ranked higher than
98% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. DEPO: 6.91 )
DEPO' s 10-Year EV-to-EBIT Range
Min: -208.4   Max: 130
Current: 6.91

-208.4
130
Shiller P/E 61.54
DEPO's Shiller P/E is ranked higher than
78% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.40 vs. DEPO: 61.54 )
DEPO' s 10-Year Shiller P/E Range
Min: 21.62   Max: 123.75
Current: 61.54

21.62
123.75
Current Ratio 5.45
DEPO's Current Ratio is ranked higher than
87% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. DEPO: 5.45 )
DEPO' s 10-Year Current Ratio Range
Min: 0.57   Max: 56
Current: 5.45

0.57
56
Quick Ratio 5.39
DEPO's Quick Ratio is ranked higher than
89% of the 890 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. DEPO: 5.39 )
DEPO' s 10-Year Quick Ratio Range
Min: 0.57   Max: 56
Current: 5.39

0.57
56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.39
DEPO's Price/Net Cash is ranked higher than
90% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DEPO: 12.39 )
DEPO' s 10-Year Price/Net Cash Range
Min: 3.68   Max: 127
Current: 12.39

3.68
127
Price/Net Current Asset Value 9.90
DEPO's Price/Net Current Asset Value is ranked higher than
88% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. DEPO: 9.90 )
DEPO' s 10-Year Price/Net Current Asset Value Range
Min: 3.44   Max: 44.91
Current: 9.9

3.44
44.91
Price/Tangible Book 4.90
DEPO's Price/Tangible Book is ranked higher than
71% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. DEPO: 4.90 )
DEPO' s 10-Year Price/Tangible Book Range
Min: 2.54   Max: 87
Current: 4.9

2.54
87
Price/DCF (Projected) 8.24
DEPO's Price/DCF (Projected) is ranked higher than
77% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.00 vs. DEPO: 8.24 )
DEPO' s 10-Year Price/DCF (Projected) Range
Min: 1.18   Max: 335
Current: 8.24

1.18
335
Price/Median PS Value 1.01
DEPO's Price/Median PS Value is ranked higher than
79% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. DEPO: 1.01 )
DEPO' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 123.5
Current: 1.01

0.38
123.5
Price/Graham Number 1.59
DEPO's Price/Graham Number is ranked higher than
89% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.77 vs. DEPO: 1.59 )
DEPO' s 10-Year Price/Graham Number Range
Min: 0.61   Max: 7.48
Current: 1.59

0.61
7.48
Earnings Yield (Greenblatt) 14.50
DEPO's Earnings Yield (Greenblatt) is ranked higher than
98% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. DEPO: 14.50 )
DEPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 251.9
Current: 14.5

0.8
251.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany
Depomed, Inc., was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Reports Second Quarter 2009 Financial Results Jul 30 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference Nov 20 2014
DEPOMED INC Financials Nov 14 2014
Depomed To Present At Stifel 2014 Healthcare Conference Nov 12 2014
10-Q for Depomed, Inc. Nov 08 2014
DEPOMED INC Files SEC form 10-Q, Quarterly Report Nov 06 2014
Another Solid Quarter For Depomed Nov 06 2014
Depomed beats Street 3Q forecasts Nov 05 2014
Depomed beats Street 3Q forecasts Nov 05 2014
Depomed Inc Earnings Call scheduled for 4:30 pm ET today Nov 05 2014
DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 05 2014
Depomed Reports Third Quarter 2014 Financial Results Nov 05 2014
Q3 2014 Depomed Inc Earnings Release - After Market Close Nov 05 2014
Depomed To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014 Oct 27 2014
Depomed To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014 Oct 27 2014
OxyContin, Cialis Makers Dodge Court to Beat Patent Suits Oct 02 2014
Accelerated selling means it’s time to move to cash Sep 30 2014
DEPOMED INC Files SEC form 8-K, Other Events Sep 17 2014
DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Sep 09 2014
DEPOMED INC Files SEC form 8-K, Other Events Sep 05 2014
Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for... Sep 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK